Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$12.63 - $24.47 $188,490 - $365,190
14,924 New
14,924 $352,000
Q2 2022

Aug 08, 2022

BUY
$1.72 - $3.39 $40,667 - $80,153
23,644 New
23,644 $70,000

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Y Intercept (Hong Kong) LTD Portfolio

Follow Y Intercept (Hong Kong) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.